SOURCE: Active Biotech

April 22, 2010 02:44 ET

Active Biotech AB Interim report January - March 2010

LUND, SWEDEN--(Marketwire - April 22, 2010) -


Laquinimod - Teva extends its marketing and distribution rights for laquinimod

TASQ - preparations for Phase III trials under way

ANYARA - exploratory combination data presented

57-57 - exploratory clinical trial in progress

ISI - project proceeding according to plan

RhuDex™ - preclinical studies in progress

Net sales of SEK 2.8 M (2.2)

Operating loss of SEK 51.0 M (loss: 63.7)

Loss after tax of SEK 53.5 M (loss: 62.2)

Loss per share for the period amounted to SEK 0.83 (loss: 1.21)

After the end of the period a directed share issue raised approximately SEK 149 M for the company

For further information, please contact:

Tomas Leanderson
President and CEO
Tel: +46 (0)46-19 20 95

Göran Forsberg
VP Investor Relations & Business Development
Tel: +46 (0)46-19 11 54

Hans
Kolam
CFO
Tel: +46 (0)46-19 20 44

Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00

This report is also available at www.activebiotech.com


[HUG#1406538]

Active Biotech Interim report January-March 2010: http://hugin.info/1002/R/1406538/359991.pdf

Contact Information